Abstract: Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

Abstract: Disclosed herein are engineered nucleases and nuclease systems, including chimeric nucleases and chimeric nuclease systems. Engineered and chimeric nucleases disclosed herein include nucleic acid guided nuclease. Additionally disclosed herein are methods of generating engineered nucleases and methods of using the same.

Abstract: The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

Abstract: The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

Abstract: The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

Abstract: Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

Abstract: Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

Abstract: The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

Abstract: The invention relates to a method of producing a binder comprising the steps of preparing (20) a residual material comprising amorphous alumina-rich and/or aluminium hydroxide-rich constituents, heating (30) the residual material to produce a fired material, the heating (30) of the residual material being at a temperature of >800° C.

Abstract: Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

Abstract: The invention relates to the use of a hydraulic binder containing calcium aluminate, obtainable by a method in which a) prepared amorphous residual material rich in aluminium oxide and/or aluminium hydroxide is heated after the addition of a b) calcium ion-containing binder component and c) water, for the production of a constructing material.

Abstract: A method for the manufacture of a high alumina hydraulic binder comprising hydrating a source of aluminium ions with a source of calcium ions in the presence of water to form mineral hydrates and subsequently heating said mineral hydrates to form said high alumina hydraulic binder.

Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Abstract: A method for use on a computing device for social media distribution involves registering a campaign with at least one data set related to at least one of: an age, a gender, a theme, a demographic, a jurisdiction, a location and a desired engagement rate. The campaign may be related to a social market media campaign with a predefined online handle or metadata set. From a user terminal, a database management system is accessed. The database management system is configured for compiling a set of online identities of social media users on social media websites matching one or data sets related to the campaign. At least one message including social media content associated with the online handle or metadata set is sent to a social media user. The social media user can accept to distribute social media with the online handle or metadata set from at least one private account.

Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Abstract: A social media contents proceeding method adapted to be executed on a computing device connected to the Internet, wherein the method comprises the steps of: providing a user interface on the computing device for receiving one or more criteria, which comprises one or more of age, gender, theme, number of followers, engagement rate, related to a social market media campaign with a predefined online handle; connecting to a database management system for compiling a set of online identities on social media websites matching one or more criteria; retrieving social media contents from one or more social media websites associated with the online handle and the online identities, and calculating a total amount of social media contents associated with each of the online identities with the online handle.

Abstract: Compositions and methods are provided for therapeutic treatment using recombinant Hemopexin molecules having sufficient sialyation and/or absence of neutral glycans to allow for sufficient circulation to remove free heme from a biological organism. In other embodiments, a recombinant Hemopexin molecule is provided for therapeutic treatment having a percentage of neutral glycans to total glycans in a range of from about 2 to about 30 percent as measured by HPLC after labelling with fluorescent probe 2-aminobenzoic acid. Methods of treatment and making a recombinant Hemopexin molecule are also described.

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract: The present teachings relate to compounds of Formula (I): and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula (I) and methods of use compounds of Formula (I) in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.